Globus Medical, Inc. Profile Avatar - Palmy Investing

Globus Medical, Inc.

Globus Medical, Inc., a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. It offers spine products, such as traditional fusion implants comprisin…
Medical - Devices
US, Audubon [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 14% Weak
Profitability n.A. n.A.
Fin. Growth 0% Bad
Leverage & Liquidity 17% Weak
Per Share Metrics 33% Weak
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q4 Q1 Δ in %
EV/EBITDA -4.94 75.61 79.55
Graham Fair Price -30.58 5.86 8.43
PEG 1508.48 1.71 0.11
Price/Book -0.24 1.83 1.84
Price/Cash Flow 236.09 301.93 89.83
Prices/Earnings 106.75 -252.62 122.19
Price/Sales -0.53 11.85 11.92
Price/FCF 236.09 301.93 89.83
Naive Interpretation member
01 - Valuation · Weak
Fundamentals

Profitability

Metric Q4 Q1 Δ in %
Gross Profit Margin -2.87 0.55 0.57
Operating Margin 322.90 0.07 0.02
ROA -51.30 < 0.005 < 0.005
ROE < 0.005 < 0.005 -51.75
ROIC < 0.005 < 0.005 472.59
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q4 Q1 Δ in %
Debt QOQ 0.01 < 0.005 125.04
Dividends QOQ 0.00 0.00 0.00
EBIT QOQ 24.06 3.16 -86.86
EPS QOQ 11.50 -1.48 -87.15
FCF QOQ 1.83 -0.71 -61.17
Revenue QOQ 0.61 -0.02 -97.36
Naive Interpretation member
03 - Financial Growth · Bad
Fundamentals

Leverage & Liquidity

Metric Q4 Q1 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 287.52 270.90 -5.78
Days Sales Outstanding (DSO) 73.70 79.32 7.63
Inventory Turnover 0.31 0.33 6.14
Debt/Capitalization 0.10 0.12 21.93
Quick Ratio 2.61 1.23 -52.71
Naive Interpretation member
04 - Leverage & Liquidity · Weak
Fundamentals

Per Share Metrics

Metric Q4 Q1 Δ in %
Book Value 29.00 28.98 -0.06
Cash 3.76 3.21 -14.53
Capex -0.17 -0.21 -27.18
Free Cash Flow 0.59 0.18 -70.34
Revenue 4.47 4.48 0.24
Naive Interpretation member
05 - Per Share Metrics · Weak
Fundamentals

Financial Health

Metric Q4 Q1 Δ in %
Current Ratio 4.88 2.33 -52.36
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA 0.57 1.77 209.81
Naive Interpretation Member
06 - Financial Health · Bad
End of GMED's Analysis
CIK: 1237831 CUSIP: 379577208 ISIN: US3795772082 LEI: - UEI: -
Secondary Listings
GMED has no secondary listings inside our databases.